

**Investigation of the pathogenic agent in a *Drosophila*
model of polyglutamine disease**

A thesis submitted for the degree of Doctor of Philosophy, March 2006

Catherine McLeod, B. Sc. (Biomed.) (Hons.)

School of Molecular and Biomedical Sciences, Discipline of Genetics
Centre for the Molecular Genetics of Development,
Adelaide University

References

1. Fu YH, Kuhl DP, Pizzuti A, Pieretti M, Sutcliffe JS, Richards S, Verkerk AJ, Holden JJ, Fenwick RG, Jr., Warren ST, et al.: **Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox.** *Cell* 1991, **67**:1047-1058.
2. La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH: **Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy.** *Nature* 1991, **352**:77-79.
3. Cummings CJ, Zoghbi HY: **Fourteen and counting: unraveling trinucleotide repeat diseases.** *Human Molecular Genetics* 2000, **9**:909-916.
4. Holmes SE, O'Hearn E, Rosenblatt A, Callahan C, Hwang HS, Ingersoll-Ashworth RG, Fleisher A, Stevanin G, Brice A, Potter NT, et al.: **A repeat expansion in the gene encoding junctophilin-3 is associated with Huntington disease-like 2.** *Nature Genetics* 2001, **29**:377-378.
5. Nakamura K, Jeong SY, Uchihara T, Anno M, Nagashima K, Nagashima T, Ikeda S, Tsuji S, Kanazawa I: **SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein.** *Human Molecular Genetics* 2001, **10**:1441-1448.
6. Paterson AD, Naimark DMJ, Vincent JB, Kennedy JL, Petronis A: **Genetic anticipation in neurological and other disorders.** In *Genetic Instabilities and Hereditary Neurological Diseases*. Edited by Wells RD, Warren ST: Academic Press; 1988:413-424.
7. Richards RI: **Dynamic mutations: a decade of unstable expanded repeats in human genetic disease.** *Human Molecular Genetics* 2001, **10**:2187-2194.
8. Brais B, Bouchard JP, Xie YG, Rochefort DL, Chretien N, Tome FM, Lafreniere RG, Rommens JM, Uyama E, Nohira O, et al.: **Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy.** *Nature Genetics* 1998, **18**:164-167.
9. Zoghbi HY, Orr HT: **Glutamine repeats and neurodegeneration.** *Annual Review of Neuroscience* 2000, **23**:217-247.
10. Myers RH, Marans KS, MacDonald EM: **Huntington's disease.** In *Genetic instabilities and hereditary neurological diseases*. Edited by Wells RD, Warren ST: Academic press; 1998:301-318.
11. Trottier Y, Lutz Y, Stevanin G, Imbert G, Devys D, Cancel G, Saudou F, Weber C, David G, Tora L: **Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias.** *Nature* 1995, **378**:403-406.
12. DiFiglia M, Sapp E, Chase K, Schwarz C, Meloni A, Young C, Martin E, Vonsattel JP, Carraway R, Reeves SA, et al.: **Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons.** *Neuron* 1995, **14**:1075-1081.
13. Landwehrmeyer GB, McNeil SM, Dure LSt, Ge P, Aizawa H, Huang Q, Ambrose CM, Duyao MP, Bird ED, Bonilla E, et al.: **Huntington's disease gene: regional and cellular expression in brain of normal and affected individuals.** *Annals of Neurology* 1995, **37**:218-230.
14. Zoghbi HY: **Spinocerebellar ataxia type 1.** *Clin Neurosci* 1995, **3**:5-11.
15. Irwin S, Vandelft M, Pinchev D, Howell JL, Graczyk J, Orr HT, Truant R: **RNA association and nucleocytoplasmic shuttling by ataxin-1.** *J Cell Sci* 2005, **118**:233-242.
16. Skinner PJ, Koshy BT, Cummings CJ, Klement IA, Helin K, Servadio A, Zoghbi HY, Orr HT: **Ataxin-1 with an expanded glutamine tract alters nuclear matrix-associated structures.** *Nature* 1997, **389**:971-974.

17. Banfi S, Servadio A, Chung MY, Kwiatkowski TJ, Jr., McCall AE, Duvick LA, Shen Y, Roth EJ, Orr HT, Zoghbi HY: **Identification and characterization of the gene causing type 1 spinocerebellar ataxia.** *Nature Genetics* 1994, **7**:513-520.
18. Huynh DP, Del Bigio MR, Ho DH, Pulst SM: **Expression of ataxin-2 in brains from normal individuals and patients with Alzheimer's disease and spinocerebellar ataxia 2.** *Annals of Neurology* 1999, **45**:232-241.
19. Huynh DP, Figueroa K, Hoang N, Pulst SM: **Nuclear localization or inclusion body formation of ataxin-2 are not necessary for SCA2 pathogenesis in mouse or human.** *Nature Genetics* 2000, **26**:44-50.
20. Ralser M, Nonhoff U, Albrecht M, Lengauer T, Wanker EE, Lehrach H, Krobatsch S: **Ataxin-2 and huntingtin interact with endophilin-A complexes to function in plastin-associated pathways.** *Hum Mol Genet* 2005.
21. Cancel G, Durr A, Didierjean O, Imbert G, Burk K, Lezin A, Belal S, Benomar A, Abada-Bendib M, Vial C, et al.: **Molecular and clinical correlations in spinocerebellar ataxia 2: a study of 32 families.** *Hum Mol Genet* 1997, **6**:709-715.
22. Durr A, Stevanin G, Cancel G, Duyckaerts C, Abbas N, Didierjean O, Chneiweiss H, Benomar A, Lyon-Caen O, Julien J, et al.: **Spinocerebellar ataxia 3 and Machado-Joseph disease: clinical, molecular, and neuropathological features.** *Ann Neurol* 1996, **39**:490-499.
23. van Alfen N, Sinke RJ, Zwarts MJ, Gabreels-Festen A, Praamstra P, Kremer BP, Horstink MW: **Intermediate CAG repeat lengths (53,54) for MJD/SCA3 are associated with an abnormal phenotype.** *Ann Neurol* 2001, **49**:805-807.
24. Paulson HL, Perez MK, Trottier Y, Trojanowski JQ, Subramony SH, Das SS, Vig P, Mandel JL, Fischbeck KH, Pittman RN: **Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3.** *Neuron* 1997, **19**:333-344.
25. Burnett B, Li F, Pittman RN: **The polyglutamine neurodegenerative protein ataxin-3 binds polyubiquitylated proteins and has ubiquitin protease activity.** *Hum Mol Genet* 2003, **12**:3195-3205.
26. Mao Y, Senic-Matuglia F, Di Fiore PP, Polo S, Hodsdon ME, De Camilli P: **Deubiquitinating function of ataxin-3: Insights from the solution structure of the Josephin domain.** *Proc Natl Acad Sci U S A* 2005.
27. Zhuchenko O, Bailey J, Bonnen P, Ashizawa T, Stockton DW, Amos C, Dobyns WB, Subramony SH, Zoghbi HY, Lee CC: **Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel.** *Nat Genet* 1997, **15**:62-69.
28. Ishikawa K, Fujigasaki H, Saegusa H, Ohwada K, Fujita T, Iwamoto H, Komatsuzaki Y, Toru S, Toriyama H, Watanabe M, et al.: **Abundant expression and cytoplasmic aggregations of [alpha]1A voltage-dependent calcium channel protein associated with neurodegeneration in spinocerebellar ataxia type 6.** *Human Molecular Genetics* 1999, **8**:1185-1193.
29. Gomez CM, Thompson RM, Gammack JT, Perlman SL, Dobyns WB, Truwit CL, Zee DS, Clark HB, Anderson JH: **Spinocerebellar ataxia type 6: gaze-evoked and vertical nystagmus, Purkinje cell degeneration, and variable age of onset.** *Ann Neurol* 1997, **42**:933-950.
30. Restituito S, Thompson RM, Eliet J, Raike RS, Riedl M, Charnet P, Gomez CM: **The polyglutamine expansion in spinocerebellar ataxia type 6 causes a beta subunit-specific enhanced activation of P/Q-type calcium channels in Xenopus oocytes.** *Journal of Neuroscience* 2000, **20**:6394-6403.
31. Frontali M: **Spinocerebellar ataxia type 6: channelopathy or glutamine repeat disorder?** *Brain Research Bulletin* 2001, **56**:227-231.

32. Mantuano E, Veneziano L, Jodice C, Frontali M: **Spinocerebellar ataxia type 6 and episodic ataxia type 2: differences and similarities between two allelic disorders.** *Cytogenet Genome Res* 2003, **100**:147-153.
33. Holmberg M, Duyckaerts C, Durr A, Cancel G, Gourfinkel-An I, Damier P, Faucheux B, Trottier Y, Hirsch EC, Agid Y, et al.: **Spinocerebellar ataxia type 7 (SCA7): a neurodegenerative disorder with neuronal intranuclear inclusions.** *Hum Mol Genet* 1998, **7**:913-918.
34. Cancel G, Duyckaerts C, Holmberg M, Zander C, Yvert G, Lebre AS, Ruberg M, Faucheux B, Agid Y, Hirsch E, et al.: **Distribution of ataxin-7 in normal human brain and retina.** *Brain* 2000, **123 Pt 12**:2519-2530.
35. Lindenberg KS, Yvert G, Muller K, Landwehrmeyer GB: **Expression analysis of ataxin-7 mRNA and protein in human brain: evidence for a widespread distribution and focal protein accumulation.** *Brain Pathol* 2000, **10**:385-394.
36. Helmlinger D, Hardy S, Sasorith S, Klein F, Robert F, Weber C, Miguet L, Potier N, Van-Dorselaer A, Wurtz JM, et al.: **Ataxin-7 is a subunit of GCN5 histone acetyltransferase-containing complexes.** *Hum Mol Genet* 2004, **13**:1257-1265.
37. Koide R, Kobayashi S, Shimohata T, Ikeuchi T, Maruyama M, Saito M, Yamada M, Takahashi H, Tsuji S: **A neurological disease caused by an expanded CAG trinucleotide repeat in the TATA-binding protein gene: a new polyglutamine disease?** *Human Molecular Genetics* 1999, **8**:2047-2053.
38. Rolfs A, Koeppen AH, Bauer I, Bauer P, Buhlmann S, Topka H, Schols L, Riess O: **Clinical features and neuropathology of autosomal dominant spinocerebellar ataxia (SCA17).** *Ann Neurol* 2003, **54**:367-375.
39. van Roon-Mom WM, Reid SJ, Faull RL, Snell RG: **TATA-binding protein in neurodegenerative disease.** *Neuroscience* 2005, **133**:863-872.
40. Fujigasaki H, Martin JJ, De Deyn PP, Camuzat A, Deffond D, Stevanin G, Dermaut B, Van Broeckhoven C, Durr A, Brice A: **CAG repeat expansion in the TATA box-binding protein gene causes autosomal dominant cerebellar ataxia.** *Brain* 2001, **124**:1939-1947.
41. Sobue G, Hashizume Y, Mukai E, Hirayama M, Mitsuma T, Takahashi A: **X-linked recessive bulbospinal neuronopathy. A clinicopathological study.** *Brain* 1989, **112 (Pt 1)**:209-232.
42. Arbizu T, Santamaria J, Gomez JM, Quilez A, Serra JP: **A family with adult spinal and bulbar muscular atrophy, X-linked inheritance and associated testicular failure.** *J Neurol Sci* 1983, **59**:371-382.
43. Becher MW, Rubinsztein DC, Leggo J, Wagster MV, Stine OC, Ranen NG, Franz ML, Abbott MH, Sherr M, MacMillan JC, et al.: **Dentatorubral and pallidolusian atrophy (DRPLA). Clinical and neuropathological findings in genetically confirmed North American and European pedigrees.** *Mov Disord* 1997, **12**:519-530.
44. Takahashi H, Ohama E, Naito H, Takeda S, Nakashima S, Makifuchi T, Ikuta F: **Hereditary dentatorubral-pallidolusian atrophy: clinical and pathologic variants in a family.** *Neurology* 1988, **38**:1065-1070.
45. Burke JR, Wingfield MS, Lewis KE, Roses AD, Lee JE, Hulette C, Pericak-Vance MA, Vance JM: **The Haw River syndrome: dentatorubropallidolusian atrophy (DRPLA) in an African-American family.** *Nat Genet* 1994, **7**:521-524.
46. Nagafuchi S, Yanagisawa H, Sato K, Shirayama T, Ohsaki E, Bundo M, Takeda T, Tadokoro K, Kondo I, Murayama N, et al.: **Dentatorubral and pallidolusian atrophy expansion of an unstable CAG trinucleotide on chromosome 12p.** *Nat Genet* 1994, **6**:14-18.

47. Nagafuchi S, Yanagisawa H, Ohsaki E, Shirayama T, Tadokoro K, Inoue T, Yamada M: **Structure and expression of the gene responsible for the triplet repeat disorder, dentatorubral and pallidolusian atrophy (DRPLA).** *Nat Genet* 1994, **8**:177-182.
48. Wood JD, Nucifora FC, Jr., Duan K, Zhang C, Wang J, Kim Y, Schilling G, Sacchi N, Liu JM, Ross CA: **Atrophin-1, the dentato-rubral and pallido-lusian atrophy gene product, interacts with ETO/MTG8 in the nuclear matrix and represses transcription.** *J Cell Biol* 2000, **150**:939-948.
49. Yazawa I, Nukina N, Goto J, Kurisaki H, Hebisawa A, Kanazawa I: **Expression of dentatorubral-pallidolusian atrophy (DRPLA) proteins in patients.** *Neurosci Lett* 1997, **225**:53-56.
50. Hodgson JG, Agopyan N, Gutekunst CA, Leavitt BR, LePiane F, Singaraja R, Smith DJ, Bissada N, McCutcheon K, Nasir J, et al.: **A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration.** *Neuron* 1999, **23**:181-192.
51. Reddy PH, Williams M, Charles V, Garrett L, Pike-Buchanan L, Whetsell WO, Jr., Miller G, Tagle DA: **Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA.** *Nat Genet* 1998, **20**:198-202.
52. Ordway JM, Tallaksen-Greene S, Gutekunst CA, Bernstein EM, Cearley JA, Wiener HW, Dure LS, Lindsey R, Hersch SM, Jope RS, et al.: **Ectopically expressed CAG repeats cause intranuclear inclusions and a progressive late onset neurological phenotype in the mouse.** *Cell* 1997, **91**:753-763.
53. Hannan AJ: **Trinucleotide-repeat expansions and neurodegenerative disease: a mechanism of pathogenesis.** *Clin Exp Pharmacol Physiol* 1996, **23**:1015-1020.
54. Kakizuka A: **Degenerative ataxias: genetics, pathogenesis and animal models.** *Curr Opin Neurol* 1997, **10**:285-290.
55. Ambrose CM, Duyao MP, Barnes G, Bates GP, Lin CS, Srinidhi J, Baxendale S, Hummerich H, Lehrach H, Altherr M: **Structure and expression of the Huntington's disease gene: evidence against simple inactivation due to an expanded CAG repeat.** *Somatic Cell and Molecular Genetics* 1994, **20**:27-38.
56. Duyao MP, Auerbach AB, Ryan A, Persichetti F, Barnes GT, McNeil SM, Ge P, Vonsattel JP, Gusella JF, Joyner AL: **Inactivation of the mouse Huntington's disease gene homolog Hdh.** *Science* 1995, **269**:407-410.
57. Wieacker PF, Knoke I, Jakubiczka S: **Clinical and molecular aspects of androgen receptor defects.** *Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association* 1998, **106**:446-453.
58. Yoo SY, Pennesi ME, Weeber EJ, Xu B, Atkinson R, Chen S, Armstrong DL, Wu SM, Sweatt JD, Zoghbi HY: **SCA7 knockin mice model human SCA7 and reveal gradual accumulation of mutant ataxin-7 in neurons and abnormalities in short-term plasticity.** *Neuron* 2003, **37**:383-401.
59. Helmlinger D, Abou-Sleymane G, Yvert G, Rousseau S, Weber C, Trottier Y, Mandel JL, Devys D: **Disease progression despite early loss of polyglutamine protein expression in SCA7 mouse model.** *J Neurosci* 2004, **24**:1881-1887.
60. Moulder KL, Onodera O, Burke JR, Strittmatter WJ, Johnson EM: **Generation of neuronal intranuclear inclusions by polyglutamine-GFP: analysis of inclusion clearance and toxicity as a function of polyglutamine length.** *The Journal of Neuroscience : the Official Journal of the Society For Neuroscience* 1999, **19**:705-715.

61. Onodera O, Roses AD, Tsuji S, Vance JM, Strittmatter WJ, Burke JR: **Toxicity of expanded polyglutamine-domain proteins in Escherichia coli.** *Febs Letters* 1996, **399**:135-139.
62. Ordway JM, Cearley JA, Detloff PJ: **CAG-polyglutamine-repeat mutations: independence from gene context.** *Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences* 1999, **354**:1083-1088.
63. Burrell EN, Clark HB, Servadio A, Matilla T, Feddersen RM, Yunis WS, Duvick LA, Zoghbi HY, Orr HT: **SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat.** *Cell* 1995, **82**:937-948.
64. Fernandez-Funez P, Nino-Rosales ML, de Gouyon B, She WC, Luchak JM, Martinez P, Turiegano E, Benito J, Capovilla M, Skinner PJ, et al.: **Identification of genes that modify ataxin-1-induced neurodegeneration.** *Nature* 2000, **408**:101-106.
65. Lorenzetti D, Watase K, Xu B, Matzuk MM, Orr HT, Zoghbi HY: **Repeat instability and motor incoordination in mice with a targeted expanded CAG repeat in the Sca1 locus.** *Human Molecular Genetics* 2000, **9**:779-785.
66. Watase K, Weeber EJ, Xu B, Antalffy B, Yuva-Paylor L, Hashimoto K, Kano M, Atkinson R, Sun Y, Armstrong DL, et al.: **A Long CAG Repeat in the Mouse Sca1 Locus Replicates SCA1 Features and Reveals the Impact of Protein Solubility on Selective Neurodegeneration.** *Neuron* 2002, **34**:905-919.
67. Lin B, Nasir J, MacDonald H, Hutchinson G, Graham RK, Rommens JM, Hayden MR: **Sequence of the murine Huntington disease gene: evidence for conservation, alternate splicing and polymorphism in a triplet (CCG) repeat [corrected].** *Human Molecular Genetics* 1994, **3**:85-92.
68. White JK, Auerbach W, Duyao MP, Vonsattel JP, Gusella JF, Joyner AL, MacDonald ME: **Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion.** *Nature Genetics* 1997, **17**:404-410.
69. Usdin MT, Shelbourne PF, Myers RM, Madison DV: **Impaired synaptic plasticity in mice carrying the Huntington's disease mutation.** *Human Molecular Genetics* 1999, **8**:839-846.
70. Lin CH, Tallaksen-Greene S, Chien WM, Cearley JA, Jackson WS, Crouse AB, Ren S, Li XJ, Albin RL, Detloff PJ: **Neurological abnormalities in a knock-in mouse model of Huntington's disease.** *Human Molecular Genetics* 2001, **10**:137-144.
71. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trotter Y, Lehrach H, Davies SW, et al.: **Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice.** *Cell* 1996, **87**:493-506.
72. Karpuj MV, Becher MW, Springer JE, Chabas D, Youssef S, Pedotti R, Mitchell D, Steinman L: **Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine.** *Nature Medicine* 2002, **8**:143-149.
73. Ona VO, Li M, Vonsattel JP, Andrews LJ, Khan SQ, Chung WM, Frey AS, Menon AS, Li XJ, Stieg PE, et al.: **Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease.** *Nature* 1999, **399**:263-267.
74. Yamamoto A, Lucas JJ, Hen R: **Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease.** *Cell* 2000, **101**:57-66.
75. Zu T, Duvick LA, Kaytor MD, Berlinger MS, Zoghbi HY, Clark HB, Orr HT: **Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice.** *J Neurosci* 2004, **24**:8853-8861.

76. Ikeda H, Yamaguchi M, Sugai S, Aze Y, Narumiya S, Kakizuka A: **Expanded polyglutamine in the Machado-Joseph disease protein induces cell death in vitro and in vivo.** *Nature Genetics* 1996, **13**:196-202.
77. DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, Aronin N: **Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain.** *Science* 1997, **277**:1990-1993.
78. Goldberg YP, Nicholson DW, Rasper DM, Kalchman MA, Koide HB, Graham RK, Bromm M, Kazemi-Esfarjani P, Thornberry NA, Vaillancourt JP, et al.: **Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract.** *Nature Genetics* 1996, **13**:442-449.
79. Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, Bian J, Guo L, Farrell LA, Hersch SM, et al.: **Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease.** *Nature Medicine* 2000, **6**:797-801.
80. Warrick JM, Paulson HL, Gray Board GL, Bui QT, Fischbeck KH, Pittman RN, Bonini NM: **Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in Drosophila.** *Cell* 1998, **93**:939-949.
81. Jackson GR, Salecker I, Dong X, Yao X, Arnheim N, Faber PW, MacDonald ME, Zipursky SL: **Polyglutamine-expanded human huntingtin transgenes induce degeneration of Drosophila photoreceptor neurons.** *Neuron* 1998, **21**:633-642.
82. Wanker EE: **Protein aggregation in Huntington's and Parkinson's disease: implications for therapy.** *Molecular Medicine Today* 2000, **6**:387-391.
83. Steffan JS, Bodai L, Pallos J, Poelman M, McCampbell A, Apostol BL, Kazantsev A, Schmidt E, Zhu YZ, Greenwald M, et al.: **Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila.** *Nature* 2001, **413**:739-743.
84. Marsh JL, Walker H, Theisen H, Zhu YZ, Fielder T, Purcell J, Thompson LM: **Expanded polyglutamine peptides alone are intrinsically cytotoxic and cause neurodegeneration in Drosophila.** *Human Molecular Genetics* 2000, **9**:13-25.
85. Adams MD, Sekelsky JJ: **From sequence to phenotype: reverse genetics in Drosophila melanogaster.** *Nature Reviews Genetics* 2002:189-198.
86. Kazemi-Esfarjani P, Benzer S: **Genetic suppression of polyglutamine toxicity in Drosophila.** *Science* 2000, **287**:1837-1840.
87. Ishikawa K, Owada K, Ishida K, Fujigasaki H, Shun Li M, Tsunemi T, Ohkoshi N, Toru S, Mizutani T, Hayashi M, et al.: **Cytoplasmic and nuclear polyglutamine aggregates in SCA6 Purkinje cells.** *Neurology* 2001, **56**:1753-1756.
88. Li M, Miwa S, Kobayashi Y, Merry DE, Yamamoto M, Tanaka F, Doyu M, Hashizume Y, Fischbeck KH, Sobue G: **Nuclear inclusions of the androgen receptor protein in spinal and bulbar muscular atrophy.** *Annals of Neurology* 1998, **44**:249-254.
89. Hayashi Y, Kakita A, Yamada M, Koide R, Igarashi S, Takano H, Ikeuchi T, Wakabayashi K, Egawa S, Tsuji S, et al.: **Hereditary dentatorubral-pallidolusian atrophy: detection of widespread ubiquitinated neuronal and glial intranuclear inclusions in the brain.** *Acta Neuropathol (Berl)* 1998, **96**:547-552.
90. Davies SW, Beardsall K, Turmaine M, DiFiglia M, Aronin N, Bates GP: **Are neuronal intranuclear inclusions the common neuropathology of triplet-repeat disorders with polyglutamine-repeat expansions?** *Lancet* 1998, **351**:131-133.
91. Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA, Scherzinger E, Wanker EE, Mangiarini L, Bates GP: **Formation of neuronal**

- intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation.** *Cell* 1997, **90**:537-548.
92. Sisodia SS: **Nuclear inclusions in glutamine repeat disorders: are they pernicious, coincidental, or beneficial?** *Cell* 1998, **95**:1-4.
 93. Ross CA, Wood JD, Schilling G, Peters MF, Nucifora FC, Cooper JK, Sharp AH, Margolis RL, Borchelt DR: **Polyglutamine pathogenesis.** *Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences* 1999, **354**:1005-1011.
 94. Michalik A, Van Broeckhoven C: **Pathogenesis of polyglutamine disorders: aggregation revisited.** *Hum Mol Genet* 2003, **12 Spec No 2**:R173-186.
 95. Chai Y, Koppenhafer SL, Shoesmith SJ, Perez MK, Paulson HL: **Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro.** *Hum Mol Genet* 1999, **8**:673-682.
 96. Cummings CJ, Mancini MA, Antalffy B, DeFranco DB, Orr HT, Zoghbi HY: **Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1.** *Nature Genetics* 1998, **19**:148-154.
 97. Wilkinson KD: **Ubiquitination and deubiquitination: targeting of proteins for degradation by the proteasome.** *Seminars in Cell and Developmental Biology* 2000, **11**:141-148.
 98. Jana NR, Nukina N: **Recent advances in understanding the pathogenesis of polyglutamine diseases: involvement of molecular chaperones and ubiquitin-proteasome pathway.** *J Chem Neuroanat* 2003, **26**:95-101.
 99. Bence NF, Sampat RM, Kopito RR: **Impairment of the ubiquitin-proteasome system by protein aggregation.** *Science* 2001, **292**:1552-1555.
 100. Park Y, Hong S, Kim SJ, Kang S: **Proteasome function is inhibited by polyglutamine-expanded ataxin-1, the SCA1 gene product.** *Mol Cells* 2005, **19**:23-30.
 101. Jana NR, Zemskov EA, Wang G, Nukina N: **Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release.** *Hum Mol Genet* 2001, **10**:1049-1059.
 102. Bukau B, Horwich AL: **The Hsp70 and Hsp60 chaperone machines.** *Cell* 1998, **92**:351-366.
 103. Zander C, Takahashi J, El Hachimi KH, Fujigasaki H, Albanese V, Lebre AS, Stevanin G, Duyckaerts C, Brice A: **Similarities between spinocerebellar ataxia type 7 (SCA7) cell models and human brain: proteins recruited in inclusions and activation of caspase-3.** *Human Molecular Genetics* 2001, **10**:2569-2579.
 104. Kobayashi Y, Sobue G: **Protective effect of chaperones on polyglutamine diseases.** *Brain Research Bulletin* 2001, **56**:165-168.
 105. Cummings CJ, Sun Y, Opal P, Antalffy B, Mestril R, Orr HT, Dillmann WH, Zoghbi HY: **Over-expression of inducible HSP70 chaperone suppresses neuropathology and improves motor function in SCA1 mice.** *Human Molecular Genetics* 2001, **10**:1511-1518.
 106. Chai Y, Koppenhafer SL, Bonini NM, Paulson HL: **Analysis of the role of heat shock protein (Hsp) molecular chaperones in polyglutamine disease.** *Journal of Neuroscience* 1999, **19**:10338-10347.
 107. Warrick JM, Chan HY, Gray Board GL, Chai Y, Paulson HL, Bonini NM: **Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70.** *Nature Genetics* 1999, **23**:425-428.

108. Zhou H, Li SH, Li XJ: **Chaperone suppression of cellular toxicity of huntingtin is independent of polyglutamine aggregation.** *Journal of Biological Chemistry* 2001, **276**:48417-48424.
109. Schaffar G, Breuer P, Boteva R, Behrends C, Tzvetkov N, Strippel N, Sakahira H, Siegers K, Hayer-Hartl M, Hartl FU: **Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation.** *Mol Cell* 2004, **15**:95-105.
110. McCampbell A, Taylor JP, Taye AA, Robitschek J, Li M, Walcott J, Merry D, Chai Y, Paulson H, Sobue G, et al.: **CREB-binding protein sequestration by expanded polyglutamine.** *Human Molecular Genetics* 2000, **9**:2197-2202.
111. Dunah AW, Jeong H, Griffin A, Kim YM, Standaert DG, Hersch SM, Mouradian MM, Young AB, Tanese N, Krainc D: **Sp1 and TAFII130 Transcriptional Activity Disrupted in Early Huntington's Disease.** *Science* 2002, **2**:2.
112. McCampbell A, Fischbeck KH: **Polyglutamine and CBP: fatal attraction?** *Nature Medicine* 2001, **7**:528-530.
113. Zhang X, Smith DL, Meriin AB, Engemann S, Russel DE, Roark M, Washington SL, Maxwell MM, Marsh JL, Thompson LM, et al.: **A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo.** *Proc Natl Acad Sci U S A* 2005, **102**:892-897.
114. Parekh-Olmedo H, Wang J, Gusella JF, Kmiec EB: **Modified single-stranded oligonucleotides inhibit aggregate formation and toxicity induced by expanded polyglutamine.** *J Mol Neurosci* 2004, **24**:257-267.
115. Klement IA, Skinner PJ, Kaytor MD, Yi H, Hersch SM, Clark HB, Zoghbi HY, Orr HT: **Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice.** *Cell* 1998, **95**:41-53.
116. Saudou F, Finkbeiner S, Devys D, Greenberg ME: **Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions.** *Cell* 1998, **95**:55-66.
117. Scherzinger E, Lurz R, Turmaine M, Mangiarini L, Hollenbach B, Hasenbank R, Bates GP, Davies SW, Lehrach H, Wanker EE: **Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo.** *Cell* 1997, **90**:549-558.
118. Cummings CJ, Reinstein E, Sun Y, Antalffy B, Jiang Y, Ciechanover A, Orr HT, Beaudet AL, Zoghbi HY: **Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice.** *Neuron* 1999, **24**:879-892.
119. Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S: **Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death.** *Nature* 2004, **431**:805-810.
120. Bowman AB, Yoo SY, Dantuma NP, Zoghbi HY: **Neuronal dysfunction in a polyglutamine disease model occurs in the absence of ubiquitin-proteasome system impairment and inversely correlates with the degree of nuclear inclusion formation.** *Hum Mol Genet* 2005, **14**:679-691.
121. Ravikumar B, Vacher C, Berger Z, Davies JE, Luo S, Oroz LG, Scaravilli F, Easton DF, Duden R, O'Kane CJ, et al.: **Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease.** *Nat Genet* 2004, **36**:585-595.
122. Toyoshima Y, Yamada M, Onodera O, Shimohata M, Inenaga C, Fujita N, Morita M, Tsuji S, Takahashi H: **SCA17 homozygote showing Huntington's disease-like phenotype.** *Ann Neurol* 2004, **55**:281-286.
123. Stevanin G, Fujigasaki H, Lebre AS, Camuzat A, Jeannequin C, Dode C, Takahashi J, San C, Bellance R, Brice A, et al.: **Huntington's disease-like**

- phenotype due to trinucleotide repeat expansions in the TBP and JPH3 genes.** *Brain* 2003, **126**:1599-1603.
124. Kondo I, Ohta H, Yazaki M, Ikeda JE, Gusella JF, Kanazawa I: **Exclusion mapping of the hereditary dentatorubropallidoluysian atrophy gene from the Huntington's disease locus.** *J Med Genet* 1990, **27**:105-108.
 125. Emamian ES, Kaytor MD, Duvick LA, Zu T, Tousey SK, Zoghbi HY, Clark HB, Orr HT: **Serine 776 of ataxin-1 is critical for polyglutamine-induced disease in SCA1 transgenic mice.** *Neuron* 2003, **38**:375-387.
 126. Chen HK, Fernandez-Funez P, Acevedo SF, Lam YC, Kaytor MD, Fernandez MH, Aitken A, Skoulakis EM, Orr HT, Botas J, et al.: **Interaction of Akt-phosphorylated ataxin-1 with 14-3-3 mediates neurodegeneration in spinocerebellar ataxia type 1.** *Cell* 2003, **113**:457-468.
 127. Tsuda H, Jafar-Nejad H, Patel AJ, Sun Y, Chen HK, Rose MF, Venken KJ, Botas J, Orr HT, Bellen HJ, et al.: **The AXH domain of Ataxin-1 mediates neurodegeneration through its interaction with Gfi-1/Senseless proteins.** *Cell* 2005, **122**:633-644.
 128. Albrecht A, Mundlos S: **The other trinucleotide repeat: polyalanine expansion disorders.** *Curr Opin Genet Dev* 2005, **15**:285-293.
 129. Brown LY, Brown SA: **Alanine tracts: the expanding story of human illness and trinucleotide repeats.** *Trends Genet* 2004, **20**:51-58.
 130. Calado A, Tome FM, Brais B, Rouleau GA, Kuhn U, Wahle E, Carmo Fonseca M: **Nuclear inclusions in oculopharyngeal muscular dystrophy consist of poly(A) binding protein 2 aggregates which sequester poly(A) RNA.** *Human Molecular Genetics* 2000, **9**:2321-2328.
 131. Dorsman JC, Pepers B, Langenberg D, Kerkdijk H, Ijszenga M, Den Dunnen JT, Roos RA, Van Ommen GJ: **Strong aggregation and increased toxicity of poly-leucine over polyglutamine stretches in mammalian cells.** *Human Molecular Genetics* 2002, **11**:1487-1496.
 132. Gaspar C, Jannatipour M, Dion P, Laganriere J, Sequeiros J, Brais B, Rouleau GA: **CAG tract of MJD-1 may be prone to frameshifts causing polyalanine accumulation.** *Human Molecular Genetics* 2000, **9**:1957-1966.
 133. Toulouse A, Au-Yeung F, Gaspar C, Roussel J, Dion P, Rouleau GA: **Ribosomal frameshifting on MJD-1 transcripts with long CAG tracts.** *Hum Mol Genet* 2005, **14**:2649-2660.
 134. Koob MD, Moseley ML, Schut LJ, Benzow KA, Bird TD, Day JW, Ranum LP: **An untranslated CTG expansion causes a novel form of spinocerebellar ataxia (SCA8).** *Nature Genetics* 1999, **21**:379-384.
 135. Ikeda Y, Dalton JC, Moseley ML, Gardner KL, Bird TD, Ashizawa T, Seltzer WK, Pandolfo M, Milunsky A, Potter NT, et al.: **Spinocerebellar ataxia type 8: molecular genetic comparisons and haplotype analysis of 37 families with ataxia.** *Am J Hum Genet* 2004, **75**:3-16.
 136. Matsuura T, Yamagata T, Burgess DL, Rasmussen A, Grewal RP, Watase K, Khajavi M, McCall AE, Davis CF, Zu L, et al.: **Large expansion of the ATTCT pentanucleotide repeat in spinocerebellar ataxia type 10.** *Nature Genetics* 2000, **26**:191-194.
 137. Lin X, Ashizawa T: **Recent progress in spinocerebellar ataxia type-10 (SCA10).** *Cerebellum* 2005, **4**:37-42.
 138. Grabczyk E, Kumari D, Usdin K: **Fragile X syndrome and Friedreich's ataxia: two different paradigms for repeat induced transcript insufficiency.** *Brain Research Bulletin* 2001, **56**:367-373.
 139. Wilmot GR, Warren ST: **A new mutational basis for disease.** In *Genetic Instabilities and Hereditary Neurological Diseases*. Edited by Wells RD, Warren ST: Academic Press; 1998:3-12.

140. Holmes SE, Hearn EO, Ross CA, Margolis RL: **SCA12: an unusual mutation leads to an unusual spinocerebellar ataxia.** *Brain Research Bulletin* 2001, **56**:397-403.
141. Hagerman PJ, Greco CM, Hagerman RJ: **A cerebellar tremor/ataxia syndrome among fragile X premutation carriers.** *Cytogenet Genome Res* 2003, **100**:206-212.
142. Nemes JP, Benzow KA, Moseley ML, Ranum LP, Koob MD: **The SCA8 transcript is an antisense RNA to a brain-specific transcript encoding a novel actin-binding protein (KLHL1).** *Hum Mol Genet* 2000, **9**:1543-1551.
143. Day JW, Schut LJ, Moseley ML, Durand AC, Ranum LP: **Spinocerebellar ataxia type 8: clinical features in a large family.** *Neurology* 2000, **55**:649-657.
144. Grewal RP, Achari M, Matsuura T, Durazo A, Tayag E, Zu L, Pulst SM, Ashizawa T: **Clinical features and ATTCT repeat expansion in spinocerebellar ataxia type 10.** *Arch Neurol* 2002, **59**:1285-1290.
145. Holmes SE, O'Hearn EE, McInnis MG, Gorelick-Feldman DA, Kleiderlein JJ, Callahan C, Kwak NG, Ingersoll-Ashworth RG, Sherr M, Sumner AJ, et al.: **Expansion of a novel CAG trinucleotide repeat in the 5' region of PPP2R2B is associated with SCA12.** *Nat Genet* 1999, **23**:391-392.
146. Strack S, Zaucha JA, Ebner FF, Colbran RJ, Wadzinski BE: **Brain protein phosphatase 2A: developmental regulation and distinct cellular and subcellular localization by B subunits.** *J Comp Neurol* 1998, **392**:515-527.
147. Fujigasaki H, Verma IC, Camuzat A, Margolis RL, Zander C, Lebre AS, Jamot L, Saxena R, Anand I, Holmes SE, et al.: **SCA12 is a rare locus for autosomal dominant cerebellar ataxia: a study of an Indian family.** *Ann Neurol* 2001, **49**:117-121.
148. Sutherland GR, Richards RI: **Unusual inheritance patterns due to dynamic mutation in fragile X syndrome.** *Ciba Found Symp* 1996, **197**:119-126; discussion 126-136.
149. Tassone F, Hagerman RJ, Taylor AK, Gane LW, Godfrey TE, Hagerman PJ: **Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome.** *Am J Hum Genet* 2000, **66**:6-15.
150. Hagerman RJ, Leehey M, Heinrichs W, Tassone F, Wilson R, Hills J, Grigsby J, Gage B, Hagerman PJ: **Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X.** *Neurology* 2001, **57**:127-130.
151. Berry-Kravis E, Potanos K, Weinberg D, Zhou L, Goetz CG: **Fragile X-associated tremor/ataxia syndrome in sisters related to X-inactivation.** *Ann Neurol* 2005, **57**:144-147.
152. Jacquemont S, Hagerman RJ, Leehey MA, Hall DA, Levine RA, Brunberg JA, Zhang L, Jardini T, Gane LW, Harris SW, et al.: **Penetrance of the fragile X-associated tremor/ataxia syndrome in a premutation carrier population.** *Jama* 2004, **291**:460-469.
153. Napierala M, Michalowski D, de Mezer M, Krzyzosiak WJ: **Facile FMR1 mRNA structure regulation by interruptions in CGG repeats.** *Nucleic Acids Res* 2005, **33**:451-463.
154. Greco CM, Hagerman RJ, Tassone F, Chudley AE, Del Bigio MR, Jacquemont S, Leehey M, Hagerman PJ: **Neuronal intranuclear inclusions in a new cerebellar tremor/ataxia syndrome among fragile X carriers.** *Brain* 2002, **125**:1760-1771.
155. Brook JD, McCurrach ME, Harley HG, Buckler AJ, Church D, Aburatani H, Hunter K, Snell RG, Rundel S, Crow S, et al.: **Molecular Basis of Myotonic Dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member.** *Cell* 1992, **68**:799-808.

156. Harper PS: **Myotonic Dystrophy as a trinucleotide repeat disorder - a clinical perspective.** In *Genetic instabilities and hereditary neurological diseases*. Edited by Wells RD, Warren ST: Academic press; 1998:115-128.
157. Davis BM, McCurrach ME, Taneja KL, Singer RH, Housman DE: **Expansion of a CUG trinucleotide repeat in the 3' untranslated region of myotonic dystrophy protein kinase transcripts results in nuclear retention of transcripts.** *Proceedings of the National Academy of Sciences of the United States of America* 1997, **94**:7388-7393.
158. Jansen G, Groenen PJ, Bachner D, Jap PH, Coerwinkel M, Oerlemans F, van den Broek W, Gohlsch B, Pette D, Plomp JJ, et al.: **Abnormal myotonic dystrophy protein kinase levels produce only mild myopathy in mice.** *Nature Genetics* 1996, **13**:316-324.
159. Berul CI, Maguire CT, Aronovitz MJ, Greenwood J, Miller C, Gehrman J, Housman D, Mendelsohn ME, Reddy S: **DMPK dosage alterations result in atrioventricular conduction abnormalities in a mouse myotonic dystrophy model.** *The Journal of Clinical Investigation* 1999, **103**:R1-7.
160. Kawakami K, Ohto H, Takizawa T, Saito T: **Identification and expression of six family genes in mouse retina.** *FEBS Lett* 1996, **393**:259-263.
161. Korade-Mirnic Z, Tarleton J, Servidei S, Casey RR, Gennarelli M, Pegoraro E, Angelini C, Hoffman EP: **Myotonic dystrophy: tissue-specific effect of somatic CTG expansions on allele-specific DMAHP/SIX5 expression.** *Human Molecular Genetics* 1999, **8**:1017-1023.
162. Inukai A, Doyu M, Kato T, Liang Y, Kuru S, Yamamoto M, Kobayashi Y, Sobue G: **Reduced expression of DMAHP/SIX5 gene in myotonic dystrophy muscle.** *Muscle & Nerve* 2000, **23**:1421-1426.
163. Sarkar PS, Appukuttan B, Han J, Ito Y, Ai C, Tsai W, Chai Y, Stout JT, Reddy S: **Heterozygous loss of Six5 in mice is sufficient to cause ocular cataracts.** *Nature Genetics* 2000, **25**:110-114.
164. Klesert TR, Cho DH, Clark JI, Maylie J, Adelman J, Snider L, Yuen EC, Soriano P, Tapscott SJ: **Mice deficient in Six5 develop cataracts: implications for myotonic dystrophy.** *Nature Genetics* 2000, **25**:105-109.
165. Alwazzan M, Newman E, Hamshere MG, Brook JD: **Myotonic dystrophy is associated with a reduced level of RNA from the DMWD allele adjacent to the expanded repeat.** *Human Molecular Genetics* 1999, **8**:1491-1497.
166. Korade-Mirnic Z, Babitzke P, Hoffman E: **Myotonic dystrophy: molecular windows on a complex etiology.** *Nucleic Acids Research* 1998, **26**:1363-1368.
167. Mankodi A, Logigian E, Callahan L, McClain C, White R, Henderson D, Krym M, Thornton CA: **Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat.** *Science* 2000, **289**:1769-1773.
168. Tapscott SJ: **Deconstructing Myotonic dystrophy.** *Science* 2000, **289**:1701-1702.
169. Michalowski S, Miller JW, Urbinati CR, Paliouras M, Swanson MS, Griffith J: **Visualization of double-stranded RNAs from the myotonic dystrophy protein kinase gene and interactions with CUG-binding protein.** *Nucleic Acids Research* 1999, **27**:3534-3542.
170. Tian B, White RJ, Xia T, Welle S, Turner DH, Mathews MB, Thornton CA: **Expanded CUG repeat RNAs form hairpins that activate the double-stranded RNA-dependent protein kinase PKR.** *RNA (New York, N. Y.)* 2000, **6**:79-87.
171. Taneja KL, McCurrach M, Schalling M, Housman D, Singer RH: **Foci of trinucleotide repeat transcripts in nuclei of myotonic dystrophy cells and tissues.** *Journal of Cell Biology* 1995, **128**:995-1002.

172. Amack JD, Paguio AP, Mahadevan MS: **Cis and trans effects of the myotonic dystrophy (DM) mutation in a cell culture model.** *Human Molecular Genetics* 1999, **8**:1975-1984.
173. Miller JW, Urbinati CR, Teng Umnuay P, Stenberg MG, Byrne BJ, Thornton CA, Swanson MS: **Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy.** *The Embo Journal* 2000, **19**:4439-4448.
174. Mankodi A, Urbinati CR, Yuan QP, Moxley RT, Sansone V, Krym M, Henderson D, Schalling M, Swanson MS, Thornton CA: **Muscleblind localizes to nuclear foci of aberrant RNA in myotonic dystrophy types 1 and 2.** *Human Molecular Genetics* 2001, **10**:2165-2170.
175. Fardeai M, Rogers MT, Thorpe HM, Larkin K, Hamshere MG, Harper PS, Brook JD: **Three proteins, MBNL, MBLL and MBXL, co-localize in vivo with nuclear foci of expanded-repeat transcripts in DM1 and DM2 cells.** *Human Molecular Genetics* 2002, **11**:805-814.
176. Timchenko NA, Cai ZJ, Welm AL, Reddy S, Ashizawa T, Timchenko LT: **RNA CUG repeats sequester CUGBP1 and alter protein levels and activity of CUGBP1.** *Journal of Biological Chemistry* 2001, **276**:7820-7826.
177. Ho TH, Charlet-B N, Poulos MG, Singh G, Swanson MS, Cooper TA: **Muscleblind proteins regulate alternative splicing.** *EMBO Journal* 2004, **23**:3103-3112.
178. Philips AV, Timchenko LT, Cooper TA: **Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy.** *Science* 1998, **280**:737-741.
179. Mankodi A, Takahashi MP, Jiang H, Beck CL, Bowers WJ, Moxley RT, Cannon SC, Thornton CA: **Expanded CUG repeats trigger aberrant splicing of CIC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy.** *Molecular Cell* 2002, **10**:35-44.
180. Savkur RS, Philips AV, Cooper TA: **Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy.** *Nature Genetics* 2001, **29**:40-47.
181. Kanadia RN, Johnstone KA, Mankodi A, Lungu C, Thornton CA, Esson D, Timmers AM, Hauswirth WW, Swanson MS: **A muscleblind knockout model for myotonic dystrophy.** *Science* 2003, **302**:1978-1980.
182. Ebralidze A, Wang Y, Petkova V, Ebralidze K, Junghans RP: **RNA leaching of transcription factors disrupts transcription in myotonic dystrophy.** *Science* 2004, **303**:383-387.
183. Ranum LP, Rasmussen PF, Benzow KA, Koob MD, Day JW: **Genetic mapping of a second myotonic dystrophy locus.** *Nature Genetics* 1998, **19**:196-198.
184. Liquori CL, Ricker K, Moseley ML, Jacobsen JF, Kress W, Naylor SL, Day JW, Ranum LP: **Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9.** *Science* 2001, **293**:864-867.
185. Sobczak K, de Mezer M, Michlewski G, Krol J, Krzyzosiak WJ: **RNA structure of trinucleotide repeats associated with human neurological diseases.** *Nucleic Acids Res* 2003, **31**:5469-5482.
186. Savkur RS, Philips AV, Cooper TA, Dalton JC, Moseley ML, Ranum LP, Day JW: **Insulin receptor splicing alteration in myotonic dystrophy type 2.** *Am J Hum Genet* 2004, **74**:1309-1313.
187. Mutsuddi M, Marshall CM, Benzow KA, Koob MD, Rebay I: **The spinocerebellar ataxia 8 noncoding RNA causes neurodegeneration and associates with staufen in Drosophila.** *Curr Biol* 2004, **14**:302-308.
188. Jin P, Zarnescu DC, Zhang F, Pearson CE, Lucchesi JC, Moses K, Warren ST: **RNA-mediated neurodegeneration caused by the fragile X premutation rCGG repeats in Drosophila.** *Neuron* 2003, **39**:739-747.

189. Napierala M, Krzyzosiak WJ: **CUG repeats present in myotonin kinase RNA form metastable "slippery" hairpins.** *J Biol Chem* 1997, **272**:31079-31085.
190. Michlewski G, Krzyzosiak WJ: **Molecular architecture of CAG repeats in human disease related transcripts.** *J Mol Biol* 2004, **340**:665-679.
191. Zuker M: **Mfold web server for nucleic acid folding and hybridization prediction.** *Nucleic Acids Res* 2003, **31**:3406-3415.
192. Mizutani A, Wang L, Rajan H, Vig PJ, Alaynick WA, Thaler JP, Tsai CC: **Boat, an AXH domain protein, suppresses the cytotoxicity of mutant ataxin-1.** *Embo J* 2005, **24**:3339-3351.
193. Handa V, Yeh HJ, McPhie P, Usdin K: **The AUUCU repeats responsible for spinocerebellar ataxia type 10 form unusual RNA hairpins.** *J Biol Chem* 2005, **280**:29340-29345.
194. McLaughlin BA, Spencer C, Eberwine J: **CAG trinucleotide RNA repeats interact with RNA-binding proteins.** *Am J Hum Genet* 1996, **59**:561-569.
195. Peel AL, Rao RV, Cottrell BA, Hayden MR, Ellerby LM, Bredesen DE: **Double-stranded RNA-dependent protein kinase, PKR, binds preferentially to Huntington's disease (HD) transcripts and is activated in HD tissue.** *Human Molecular Genetics* 2001, **10**:1531-1538.
196. Williams BR: **PKR; a sentinel kinase for cellular stress.** *Oncogene* 1999, **18**:6112-6120.
197. Chang RCC, Wong AKY, Ng H-K, Hugon J: **Phosphorylation of eukaryotic initiation factor-2alpha (eIF2alpha) is associated with neuronal degeneration in Alzheimer's disease.** *Neuroreport* 2002, **13**:2429-2432.
198. Bando Y, Onuki R, Katayama T, Manabe T, Kudo T, Taira K, Tohyama M: **Double-strand RNA dependent protein kinase (PKR) is involved in the extrastriatal degeneration in Parkinson's disease and Huntington's disease.** *Neurochem Int* 2005, **46**:11-18.
199. Kino Y, Mori D, Oma Y, Takeshita Y, Sasagawa N, Ishiura S: **Muscleblind protein, MBNL1/EXP, binds specifically to CHHG repeats.** *Hum Mol Genet* 2004, **13**:495-507.
200. Ho TH, Savkur RS, Poulos MG, Mancini MA, Swanson MS, Cooper TA: **Colocalization of muscleblind with RNA foci is separable from mis-regulation of alternative splicing in myotonic dystrophy.** *J Cell Sci* 2005, **118**:2923-2933.
201. Goldberg YP, Kalchman MA, Metzler M, Nasir J, Zeisler J, Graham R, Koide HB, O-Kusky J, Sharp AH, Ross CA, et al.: **Absence of disease phenotype and intergenerational stability of the CAG repeat in transgenic mice expressing the human Huntington disease transcript.** *Human Molecular Genetics* 1996, **5**:177-185.
202. Bates GP, Mangiarini L, Mahal A, Davies SW: **Transgenic models of Huntington's disease.** *Human Molecular Genetics* 1997, **6**:1633-1637.
203. Takeyama K, Ito S, Yamamoto A, Tanimoto H, Furutani T, Kanuka H, Miura M, Tabata T, Kato S: **Androgen-dependent neurodegeneration by polyglutamine-expanded human androgen receptor in Drosophila.** *Neuron* 2002, **35**:855-864.
204. Katsuno M, Adachi H, Kume A, Li M, Nakagomi Y, Niwa H, Sang C, Kobayashi Y, Doyu M, Sobue G: **Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy.** *Neuron* 2002, **35**:843-854.
205. Yang W, Dunlap JR, Andrews RB, Wetzel R: **Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells.** *Hum Mol Genet* 2002, **11**:2905-2917.

206. Hackam AS, Singaraja R, Zhang T, Gan L, Hayden MR: **In vitro evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease.** *Human Molecular Genetics* 1999, **8**:25-33.
207. Sobczak K, Krzyzosiak WJ: **CAG repeats containing CAA interruptions form branched hairpin structures in spinocerebellar ataxia type 2 transcripts.** *J Biol Chem* 2005, **280**:3898-3910.
208. Sobczak K, Krzyzosiak WJ: **Imperfect CAG repeats form diverse structures in SCA1 transcripts.** *J Biol Chem* 2004, **279**:41563-41572.
209. Orr HT: **RNA gains a new function: a mediator of neurodegeneration.** *Trends Neurosci* 2004, **27**:233-234.
210. Gatchel JR, Zoghbi HY: **Diseases of unstable repeat expansion: mechanisms and common principles.** *Nat Rev Genet* 2005, **6**:743-755.
211. Dickson BJ, Hafen E: **Genetic dissection of eye development in *Drosophila*.** In *The Development of Drosophila Melanogaster*. Edited by Bate M, Martinex Arias A: Cold Spring Harbour Laboratory Press; 1993:1327-1362. vol II.]
212. Sambrook J, Fritsch EF, Maniatis T: *Molecular Cloning: A laboratory manual, 2nd edition*: Cold Spring Harbor Laboratory Press; 1989.
213. Ordway JM, Detloff PJ: **In vitro synthesis and cloning of long CAG repeats.** *Biotechniques* 1996, **21**:609-610, 612.
214. Takahashi N, Sasagawa N, Suzuki K, Ishiura S: **Synthesis of long trinucleotide repeats in vitro.** *Neuroscience Letters* 1999, **262**:45-48.
215. Mathews DH, Sabina J, Zuker M, Turner DH: **Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure.** *J Mol Biol* 1999, **288**:911-940.
216. Brand AH, Perrimon N: **Targeted gene expression as a means of altering cell fates and generating dominant phenotypes.** *Development* 1993, **118**:401-415.
217. Rubin GM, Spradling AC: **Genetic transformation of *Drosophila* with transposable element vectors.** *Science* 1982, **218**:348-353.
218. Ellis MC, O'Neill EM, Rubin GM: **Expression of *Drosophila* glass protein and evidence for negative regulation of its activity in non-neuronal cells by another DNA-binding protein.** *Development* 1993, **119**:855-865.
219. Kramer JM, Staveley BE: **GAL4 causes developmental defects and apoptosis when expressed in the developing eye of *Drosophila melanogaster*.** *Genet Mol Res* 2003, **2**:43-47.
220. Spradling AC, Rubin GM: **The effect of chromosomal position on the expression of the *Drosophila* xanthine dehydrogenase gene.** *Cell* 1983, **34**:47-57.
221. Valencia-Sanchez MA, Maquat LE: **An enemy within: fly reconnaissance deploys an endonuclease to destroy nonsense-containing mRNA.** *Trends Cell Biol* 2004, **14**:594-597.
222. Aronin N, Chase K, Young C, Sapp E, Schwarz C, Matta N, Kornreich R, Landwehrmeyer B, Bird E, Beal MF, et al.: **CAG expansion affects the expression of mutant Huntingtin in the Huntington's disease brain.** *Neuron* 1995, **15**:1193-1201.
223. Rankin J, Wyttenbach A, Rubinsztein DC: **Intracellular green fluorescent protein-polyalanine aggregates are associated with cell death.** *Biochem J* 2000, **348 Pt 1**:15-19.
224. Ravikumar B, Duden R, Rubinsztein DC: **Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy.** *Human Molecular Genetics* 2002, **11**:1107-1117.
225. Oma Y, Kino Y, Sasagawa N, Ishiura S: **Intracellular localization of homopolymeric amino acid-containing proteins expressed in mammalian cells.** *J Biol Chem* 2004, **279**:21217-21222.

226. McLeod CJ, O'Keefe LV, Richards RI: **The pathogenic agent in *Drosophila* models of 'polyglutamine' diseases.** *Hum Mol Genet* 2005, **14**:1041-1048.
227. Higashiyama H, Hirose F, Yamaguchi M, Inoue YH, Fujikake N, Matsukage A, Kakizuka A: **Identification of ter94, *Drosophila* VCP, as a modulator of polyglutamine-induced neurodegeneration.** *Cell Death Differ* 2002, **9**:264-273.
228. Jackson SM, Whitworth AJ, Greene JC, Libby RT, Baccam SL, Pallanck LJ, La Spada AR: **A SCA7 CAG/CTG repeat expansion is stable in *Drosophila melanogaster* despite modulation of genomic context and gene dosage.** *Gene* 2005, **347**:35-41.
229. Berger Z, Davies JE, Luo S, Pasco MY, Majoul I, O'Kane C J, Rubinsztein DC: **Deleterious and protective properties of an aggregate-prone protein with a polyalanine expansion.** *Hum Mol Genet* 2005.
230. Kovtun IV, McMurray CT: **Trinucleotide expansion in haploid germ cells by gap repair.** *Nature Genetics* 2001, **27**:407-411.
231. Manley K, Shirley TL, Flaherty L, Messer A: **Msh2 deficiency prevents in vivo somatic instability of the CAG repeat in Huntington disease transgenic mice.** *Nature Genetics* 1999, **23**:471-473.
232. Takashima H, Boerkoel CF, John J, Saifi GM, Salih MA, Armstrong D, Mao Y, Quioco FA, Roa BB, Nakagawa M, et al.: **Mutation of TDP1, encoding a topoisomerase I-dependent DNA damage repair enzyme, in spinocerebellar ataxia with axonal neuropathy.** *Nat Genet* 2002, **32**:267-272.
233. Pouliot JJ, Yao KC, Robertson CA, Nash HA: **Yeast gene for a Tyr-DNA phosphodiesterase that repairs topoisomerase I complexes.** *Science* 1999, **286**:552-555.
234. Yang SW, Burgin AB, Jr., Huizenga BN, Robertson CA, Yao KC, Nash HA: **A eukaryotic enzyme that can disjoin dead-end covalent complexes between DNA and type I topoisomerases.** *Proc Natl Acad Sci U S A* 1996, **93**:11534-11539.
235. Moreira MC, Barbot C, Tachi N, Kozuka N, Uchida E, Gibson T, Mendonca P, Costa M, Barros J, Yanagisawa T, et al.: **The gene mutated in ataxia-ocular apraxia 1 encodes the new HIT/Zn-finger protein aprataxin.** *Nat Genet* 2001, **29**:189-193.
236. Date H, Onodera O, Tanaka H, Iwabuchi K, Uekawa K, Igarashi S, Koike R, Hiroi T, Yuasa T, Awaya Y, et al.: **Early-onset ataxia with ocular motor apraxia and hypoalbuminemia is caused by mutations in a new HIT superfamily gene.** *Nat Genet* 2001, **29**:184-188.
237. Clements PM, Breslin C, Deeks ED, Byrd PJ, Ju L, Bieganowski P, Brenner C, Moreira MC, Taylor AM, Caldecott KW: **The ataxia-oculomotor apraxia 1 gene product has a role distinct from ATM and interacts with the DNA strand break repair proteins XRCC1 and XRCC4.** *DNA Repair (Amst)* 2004, **3**:1493-1502.
238. Mosesso P, Piane M, Palitti F, Pepe G, Penna S, Chessa L: **The novel human gene aprataxin is directly involved in DNA single-strand-break repair.** *Cell Mol Life Sci* 2005, **62**:485-491.
239. Rotman G, Shiloh Y: **ATM: from gene to function.** *Hum Mol Genet* 1998, **7**:1555-1563.
240. van Gent DC, Hoeijmakers JHJ, Kanaar R: **Chromosomal stability and the DNA double-stranded break connection.** *Nature Reviews Genetics* *Nat Rev Genet* 2001, **2**:196-206.
241. Rapin I, Lindenbaum Y, Dickson DW, Kraemer KH, Robbins JH: **Cockayne syndrome and xeroderma pigmentosum.** *Neurology* 2000, **55**:1442-1449.

242. Lehmann AR: **DNA repair-deficient diseases, xeroderma pigmentosum, Cockayne syndrome and trichothiodystrophy.** *Biochimie* 2003, **85**:1101-1111.
243. Tomkinson AE, Mackey ZB: **Structure and function of mammalian DNA ligases.** *Mutat Res* 1998, **407**:1-9.
244. Gao Y, Sun Y, Frank KM, Dikkes P, Fujiwara Y, Seidl KJ, Sekiguchi JM, Rathbun GA, Swat W, Wang J, et al.: **A critical role for DNA end-joining proteins in both lymphogenesis and neurogenesis.** *Cell* 1998, **95**:891-902.
245. Lee Y, Barnes DE, Lindahl T, McKinnon PJ: **Defective neurogenesis resulting from DNA ligase IV deficiency requires Atm.** *Genes Dev* 2000, **14**:2576-2580.
246. Frank KM, Sharpless NE, Gao Y, Sekiguchi JM, Ferguson DO, Zhu C, Manis JP, Horner J, DePinho RA, Alt FW: **DNA ligase IV deficiency in mice leads to defective neurogenesis and embryonic lethality via the p53 pathway.** *Mol Cell* 2000, **5**:993-1002.
247. McMurray CT: **To die or not to die: DNA repair in neurons.** *Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis* 2005, **577**:260-274.
248. Caldecott KW: **DNA single-strand breaks and neurodegeneration.** *DNA Repair* 2004, **3**:875-882.
249. Nospikel T, Hanawalt PC: **DNA repair in terminally differentiated cells.** *DNA Repair (Amst)* 2002, **1**:59-75.
250. Mellon I: **Transcription-coupled repair: a complex affair.** *Mutat Res* 2005, **577**:155-161.
251. Kruman, II, Wersto RP, Cardozo-Pelaez F, Smilenov L, Chan SL, Chrest FJ, Emokpae R, Jr., Gorospe M, Mattson MP: **Cell cycle activation linked to neuronal cell death initiated by DNA damage.** *Neuron* 2004, **41**:549-561.
252. Husseman JW, Nochlin D, Vincent I: **Mitotic activation: a convergent mechanism for a cohort of neurodegenerative diseases.** *Neurobiology of Aging* 2000, **21**:815-828.
253. Sutherland GR, Richards RI: **Fragile sites-cytogenetic similarity with molecular diversity.** *Am J Hum Genet* 1999, **64**:354-359.
254. Freudenreich CH, Kantrow SM, Zakian VA: **Expansion and length-dependent fragility of CTG repeats in yeast.** *Science* 1998, **279**:853-856.
255. Callahan JL, Andrews KJ, Zakian VA, Freudenreich CH: **Mutations in yeast replication proteins that increase CAG/CTG expansions also increase repeat fragility.** *Mol Cell Biol* 2003, **23**:7849-7860.
256. Pelletier R, Krasilnikova MM, Samadashwily GM, Lahue R, Mirkin SM: **Replication and expansion of trinucleotide repeats in yeast.** *Mol Cell Biol* 2003, **23**:1349-1357.
257. Samadashwily GM, Raca G, Mirkin SM: **Trinucleotide repeats affect DNA replication in vivo.** *Nat Genet* 1997, **17**:298-304.
258. Michel B, Ehrlich SD, Uzest M: **DNA double-strand breaks caused by replication arrest.** *Embo J* 1997, **16**:430-438.
259. Lahiri M, Gustafson TL, Majors ER, Freudenreich CH: **Expanded CAG repeats activate the DNA damage checkpoint pathway.** *Mol Cell* 2004, **15**:287-293.
260. Freudenreich CH, Lahiri M: **Structure-forming CAG/CTG repeat sequences are sensitive to breakage in the absence of Mrc1 checkpoint function and S-phase checkpoint signaling: implications for trinucleotide repeat expansion diseases.** *Cell Cycle* 2004, **3**:1370-1374.
261. Giuliano P, De Cristofaro T, Affaitati A, Pizzulo GM, Feliciello A, Criscuolo C, De Michele G, Filla A, Avvedimento EV, Varrone S: **DNA damage induced by polyglutamine-expanded proteins.** *Hum Mol Genet* 2003, **12**:2301-2309.

262. Wyttenbach A, Sauvageot O, Carmichael J, Diaz-Latoud C, Arrigo A-P, Rubinsztein DC: **Heat shock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by huntingtin.** *Hum. Mol. Genet.* 2002, **11**:1137-1151.
263. Potaman VN, Oussatcheva EA, Lyubchenko YL, Shlyakhtenko LS, Bidichandani SI, Ashizawa T, Sinden RR: **Length-dependent structure formation in Friedreich ataxia (GAA)_n*(TTC)_n repeats at neutral pH.** *Nucleic Acids Res* 2004, **32**:1224-1231.
264. Napierala M, Dere R, Vetcher A, Wells RD: **Structure-dependent recombination hot spot activity of GAA.TTC sequences from intron 1 of the Friedreich's ataxia gene.** *J Biol Chem* 2004, **279**:6444-6454.
265. Adachi H, Kume A, Li M, Nakagomi Y, Niwa H, Do J, Sang C, Kobayashi Y, Doyu M, Sobue G: **Transgenic mice with an expanded CAG repeat controlled by the human AR promoter show polyglutamine nuclear inclusions and neuronal dysfunction without neuronal cell death.** *Human Molecular Genetics* 2001, **10**:1039-1048.
266. Abou-Sleymane G, Chalmel F, Helmlinger D, Lardenois A, Thibault C, Weber C, Merienne K, Mandel JL, Poch O, Devys D, et al.: **Polyglutamine expansion causes neurodegeneration by altering the neuronal differentiation program.** *Hum Mol Genet* 2006, **15**:691-703.
267. Brenner C: **Hint, Fhit, and GalT: function, structure, evolution, and mechanism of three branches of the histidine triad superfamily of nucleotide hydrolases and transferases.** *Biochemistry* 2002, **41**:9003-9014.
268. Sullivan W, Fogarty P, Theurkauf W: **Mutations affecting the cytoskeletal organization of syncytial Drosophila embryos.** *Development* 1993, **118**:1245-1254.
269. van Daal A, White EM, Gorovsky MA, Elgin SC: **Drosophila has a single copy of the gene encoding a highly conserved histone H2A variant of the H2A.F/Z type.** *Nucleic Acids Res* 1988, **16**:7487-7497.
270. Gorski MM, Eeken JC, de Jong AW, Klink I, Loos M, Romeijn RJ, van Veen BL, Mullenders LH, Ferro W, Pastink A: **The Drosophila melanogaster DNA Ligase IV gene plays a crucial role in the repair of radiation-induced DNA double-strand breaks and acts synergistically with Rad54.** *Genetics* 2003, **165**:1929-1941.
271. Rong YS, Titen SW, Xie HB, Golic MM, Bastiani M, Bandyopadhyay P, Olivera BM, Brodsky M, Rubin GM, Golic KG: **Targeted mutagenesis by homologous recombination in D. melanogaster.** *Genes Dev.* 2002, **16**:1568-1581.
272. van Daal A, Elgin SC: **A histone variant, H2AvD, is essential in Drosophila melanogaster.** *Mol Biol Cell* 1992, **3**:593-602.
273. Hirokawa N, Takemura R: **Molecular motors in neuronal development, intracellular transport and diseases.** *Curr Opin Neurobiol* 2004, **14**:564-573.
274. Reid E, Kloos M, Ashley-Koch A, Hughes L, Bevan S, Svenson IK, Graham FL, Gaskell PC, Dearlove A, Pericak-Vance MA, et al.: **A kinesin heavy chain (KIF5A) mutation in hereditary spastic paraplegia (SPG10).** *Am J Hum Genet* 2002, **71**:1189-1194.
275. Zhao C, Takita J, Tanaka Y, Setou M, Nakagawa T, Takeda S, Yang HW, Terada S, Nakata T, Takei Y, et al.: **Charcot-Marie-Tooth disease type 2A caused by mutation in a microtubule motor KIF1Bbeta.** *Cell* 2001, **105**:587-597.
276. Hafezparast M, Klocke R, Ruhrberg C, Marquardt A, Ahmad-Annur A, Bowen S, Lalli G, Witherden AS, Hummerich H, Nicholson S, et al.: **Mutations in dynein link motor neuron degeneration to defects in retrograde transport.** *Science* 2003, **300**:808-812.

277. Piccioni F, Pinton P, Simeoni S, Pozzi P, Fascio U, Vismara G, Martini L, Rizzuto R, Poletti A: **Androgen receptor with elongated polyglutamine tract forms aggregates that alter axonal trafficking and mitochondrial distribution in motor neuronal processes.** *Faseb J* 2002, **16**:1418-1420.
278. Gunawardena S, Her LS, Bruschi RG, Laymon RA, Niesman IR, Gordesky-Gold B, Sintasath L, Bonini NM, Goldstein LS: **Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila.** *Neuron* 2003, **40**:25-40.
279. Szebenyi G, Morfini GA, Babcock A, Gould M, Selkoe K, Stenoien DL, Young M, Faber PW, MacDonald ME, McPhaul MJ, et al.: **Neuropathogenic forms of huntingtin and androgen receptor inhibit fast axonal transport.** *Neuron* 2003, **40**:41-52.
280. McQuarrie IG, Brady ST, Lasek RJ: **Retardation in the slow axonal transport of cytoskeletal elements during maturation and aging.** *Neurobiol Aging* 1989, **10**:359-365.
281. Sickles DW, Brady ST, Testino A, Friedman MA, Wrenn RW: **Direct effect of the neurotoxicant acrylamide on kinesin-based microtubule motility.** *J Neurosci Res* 1996, **46**:7-17.
282. Saxton WM, Hicks J, Goldstein LS, Raff EC: **Kinesin heavy chain is essential for viability and neuromuscular functions in Drosophila, but mutants show no defects in mitosis.** *Cell* 1991, **64**:1093-1102.
283. Bowman AB, Patel-King RS, Benashski SE, McCaffery JM, Goldstein LS, King SM: **Drosophila roadblock and Chlamydomonas LC7: a conserved family of dynein-associated proteins involved in axonal transport, flagellar motility, and mitosis.** *J Cell Biol* 1999, **146**:165-180.
284. Holzbaur EL: **Motor neurons rely on motor proteins.** *Trends Cell Biol* 2004, **14**:233-240.
285. Schroer TA: **Dynactin.** *Annu Rev Cell Dev Biol* 2004, **20**:759-779.
286. Lee WC, Yoshihara M, Littleton JT: **Cytoplasmic aggregates trap polyglutamine-containing proteins and block axonal transport in a Drosophila model of Huntington's disease.** *Proc Natl Acad Sci U S A* 2004, **101**:3224-3229.
287. Barnes DE, Stamp G, Rosewell I, Denzel A, Lindahl T: **Targeted disruption of the gene encoding DNA ligase IV leads to lethality in embryonic mice.** *Curr Biol* 1998, **8**:1395-1398.
288. Duffy JB: **GAL4 system in Drosophila: a fly geneticist's Swiss army knife.** *Genesis* 2002, **34**:1-15.
289. Elefant F, Palter KB: **Tissue-specific expression of dominant negative mutant Drosophila HSC70 causes developmental defects and lethality.** *Mol Biol Cell* 1999, **10**:2101-2117.
290. Chan HY, Warrick JM, Gray-Board GL, Paulson HL, Bonini NM: **Mechanisms of chaperone suppression of polyglutamine disease: selectivity, synergy and modulation of protein solubility in Drosophila.** *Human Molecular Genetics* 2000, **9**:2811-2820.
291. Chan HY, Warrick JM, Andriola I, Merry D, Bonini NM: **Genetic modulation of polyglutamine toxicity by protein conjugation pathways in Drosophila.** *Hum Mol Genet* 2002, **11**:2895-2904.
292. Bae BI, Xu H, Igarashi S, Fujimuro M, Agrawal N, Taya Y, Hayward SD, Moran TH, Montell C, Ross CA, et al.: **p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease.** *Neuron* 2005, **47**:29-41.
293. Olsson JE, Gordon JW, Pawlyk BS, Roof D, Hayes A, Molday RS, Mukai S, Cowley GS, Berson EL, Dryja TP: **Transgenic mice with a rhodopsin mutation (Pro23His): a mouse model of autosomal dominant retinitis pigmentosa.** *Neuron* 1992, **9**:815-830.

294. Beaulieu JM, Jacomy H, Julien JP: **Formation of intermediate filament protein aggregates with disparate effects in two transgenic mouse models lacking the neurofilament light subunit.** *J Neurosci* 2000, **20**:5321-5328.
295. Szebenyi G, Smith GM, Li P, Brady ST: **Overexpression of neurofilament H disrupts normal cell structure and function.** *J Neurosci Res* 2002, **68**:185-198.
296. Houseley JM, Wang Z, Brock GJ, Soloway J, Artero R, Perez-Alonso M, O'Dell KM, Monckton DG: **Myotonic dystrophy associated expanded CUG repeat muscleblind positive ribonuclear foci are not toxic to Drosophila.** *Hum Mol Genet* 2005, **14**:873-883.
297. Willemsen R, Hoogeveen-Westerveld M, Reis S, Holstege J, Severijnen LA, Nieuwenhuizen IM, Schrier M, van Unen L, Tassone F, Hoogeveen AT, et al.: **The FMR1 CGG repeat mouse displays ubiquitin-positive intranuclear neuronal inclusions; implications for the cerebellar tremor/ataxia syndrome.** *Hum Mol Genet* 2003, **12**:949-959.
298. LaCount DJ, Hanson SF, Schneider CL, Friesen PD: **Caspase inhibitor P35 and inhibitor of apoptosis Op-IAP block in vivo proteolytic activation of an effector caspase at different steps.** *J Biol Chem* 2000, **275**:15657-15664.
299. Hay BA, Wolff T, Rubin GM: **Expression of baculovirus P35 prevents cell death in Drosophila.** *Development* 1994, **120**:2121-2129.
300. Ghosh S, Feany MB: **Comparison of pathways controlling toxicity in the eye and brain in Drosophila models of human neurodegenerative diseases.** *Hum Mol Genet* 2004, **13**:2011-2018.
301. La Spada AR, Fu YH, Sopher BL, Libby RT, Wang X, Li LY, Einum DD, Huang J, Possin DE, Smith AC, et al.: **Polyglutamine-expanded ataxin-7 antagonizes CRX function and induces cone-rod dystrophy in a mouse model of SCA7.** *Neuron* 2001, **31**:913-927.
302. Yu Z, Dadgar N, Albertelli M, Scheller A, Albin RL, Robins DM, Lieberman AP: **Abnormalities of Germ Cell Maturation and Sertoli Cell Cytoskeleton in Androgen Receptor 113 CAG Knock-In Mice Reveal Toxic Effects of the Mutant Protein.** *Am J Pathol* 2006, **168**:195-204.
303. Leavitt BR, Guttman JA, Hodgson JG, Kimel GH, Singaraja R, Vogl AW, Hayden MR: **Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo.** *Am J Hum Genet* 2001, **68**:313-324.
304. Hughes RE, Lo RS, Davis C, Strand AD, Neal CL, Olson JM, Fields S: **Altered transcription in yeast expressing expanded polyglutamine.** *Proc Natl Acad Sci U S A* 2001, **98**:13201-13206.
305. Luthi-Carter R, Strand AD, Hanson SA, Kooperberg C, Schilling G, La Spada AR, Merry DE, Young AB, Ross CA, Borchelt DR, et al.: **Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects.** *Human Molecular Genetics* 2002, **11**:1927-1937.
306. Nucifora FC, Jr., Sasaki M, Peters MF, Huang H, Cooper JK, Yamada M, Takahashi H, Tsuji S, Troncoso J, Dawson VL, et al.: **Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity.** *Science* 2001, **291**:2423-2428.
307. Miller JW, Urbinati CR, Teng-Umnuay P, Stenberg MG, Byrne BJ, Thornton CA, Swanson MS: **Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy.** *The Embo Journal* 2000, **19**:4439-4448.